EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cerebral toxoplasmosis in HIV-infected patients: a retrospective cohort study between 2015 and 2020, in Abidjan (Côte d’Ivoire).

Abel Christian Tanoh, Muriel Amon-Tanoh Tchwa, Claude Valéry Cédric Aka Kadjo Kadjo, Fiacre Delors Offoumou, Désirée Aka Arlette, Evelyne Aka-Anghui Diarra, Berhe Assi

East African Journal of Neurological Sciences · 2025

DOI: 10.4314/eajns.v4i2.3 ↗
AbstractBibliografische Angaben

Abstract

Objective: To describe the profile of HIV patients treated for cerebral toxoplasmosis in a university hospital. Methods: A retrospective single-centre cohort study was carried out from 2015 to 2020. The study was carried out at Cocody Teaching Hospital's neurology department in Abidjan, Côte d'Ivoire. Results: A total of 75 patients with cerebral toxoplasmosis were studied. The male-to-female sex ratio was 0.56, and the mean age was 42.33 ± 10.907 years. Fifty-six percent (56%) of patients were single, while 41.3% were in a relationship. About 54.7% of these patients had known serological status, and 34.7% had received antiretroviral treatment. The average duration of inpatient hospitalisation was 12.92 ± 7.647 days. The most common clinical signs were limb weakness (31.9%) and altered consciousness (29.6%), with symptom onset occurring gradually in 86.7%. Suppurative encephalitis accounted for 62.7%. Cotrimoxazole (CTX) was the primary treatment (96%). The mortality rate was estimated at 4%. Conclusion: Cerebral toxoplasmosis is still significant in HIV/AIDS infection, and the absence or non-compliance with combination antiretroviral therapy (cART) remains an essential determinant in its incidence.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →